EXICURE, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
EXICURE, INC. (XCUR) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-25.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2022-03-25
- EXICURE, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-12-31 was $0.00.
- EXICURE, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-12-31 was $0.00.
- EXICURE, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-12-31 was $0.00.
- EXICURE, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- EXICURE, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $8.15M.
- EXICURE, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2019 was $0.00.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | $0.00 10-K · filed 2022-03-25 | |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-19 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | $8.15M 10-K · filed 2022-03-25 | |
| 2020-09-30 | $8.15M 10-Q · filed 2021-11-19 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $0.00 10-K · filed 2021-03-11 | |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |